Research Article
A New Model Based on 25-Hydroxyvitamin D3 for Predicting Active Crohn’s Disease in Chinese Patients
Table 1
Demographic and clinical characteristics.
| | Group with 25(OH)D3 ≤ 20 ng/ml | Group with 25(OH)D3 > 20 ng/ml | |
| | Gender, (%) | | | 0.005 | | Male | 197 (68.9%) | 52 (86.7%) | | | Female | 89 (31.1%) | 8 (13.3%) | | | Median age, years (IQR) | 26 (20–35) | 27 (21–44) | 0.212 | | Median disease duration, years (IQR) | 2.0 (0.5–4.4) | 1.5 (0.5–5.2) | 0.741 | | Disease location, (%) | | | 0.790 | | L1 | 64 (22.4%) | 10 (16.7%) | | | L2 | 34 (11.9%) | 7 (11.7%) | | | L3 | 169 (59.1%) | 39 (65.0%) | | | L4 | 19 (6.4%) | 4 (6.7%) | | | Disease behavior, (%) | | | 0.308 | | B1 | 184 (64.3%) | 45 (75.0%) | | | B2 | 69 (24.1%) | 9 (15.0%) | | | B3 | 40 (14.0%) | 8 (13.3%) | | | Perianal lesions, (%) | 93 (32.5%) | 20 (33.3%) | 0.902 | | Extraintestinal manifestations, (%) | 42 (14.7%) | 11 (18.3%) | 0.476 | | Previous bowel surgery, (%) | 45 (15.7%) | 15 (25.0%) | 0.085 | | Previous resection of terminal ileum, (%) | 38 (13.3%) | 12 (20.0%) | 0.179 | | Previous medications, (%) | | | | | 5-Aminosalicylic acid | 120 (42.0%) | 25 (41.7%) | 0.967 | | Corticosteroids | 42 (14.7%) | 8 (13.3%) | 0.787 | | Azathioprine/6-mercaptopurine | 22 (7.7%) | 7 (11.7%) | 0.312 | | Methotrexate | 1 (0.3%) | 0 (0.0%) | 0.646 | | Thalidomide | 8 (2.8%) | 2 (3.3%) | 0.822 | | Infliximab | 6 (2.1%) | 2 (3.3%) | 0.563 | | Sun exposure | | | 0.886 | | Low (from October to March) | 124 (43.4%) | 27 (45.0%) | | | High (from April to September) | 162 (56.6%) | 33 (55.0%) | |
|
|
According to the Montreal classification: L1, terminal ileum; L2, colon; L3, ileocolon; L4, UPG; B1, nonstricturing nonpenetrating; B2, stricturing, B3, penetrating.
|
